Coripharma is a European pharmaceutical company, built on solid heritage. Our experienced team offers out-licensing and contract manufacturing services to pharmaceutical companies. Coripharma specializes in generic pharmaceutical products, solid oral dosage forms.

Coripharma

Ponatinib is based on the reference product Iclusig®, used in the treatment of certain forms of leukemia. Completing this dossier showcases Coripharma’s strong technical capabilities and the effective collaboration across Coripharma’s development functions.

This milestone reflects the exceptional work and the strong cross‑functional collaboration that continues to drive Coripharma’s development pipeline forward. With the dossier now finalized, the planned submission in March 2026 positions our partners strategically for timely market access.

By advancing Ponatinib toward submission, Coripharma reinforces its commitment to expanding its oncology portfolio, supporting partners worldwide, and contributing to broader patient access to critical treatments.

Coripharma is pleased to announce the completion of its Ponatinib dossier, representing another key achievement in our ongoing commitment to advancing high‑quality generic oncology medicines.

Coripharma Finalizes Ponatinib Dossier, Targeting March 2026 Submission

About us

Services

Sustainability

Careers

Latest News

Coripharma Finalizes Ponatinib Dossier, Targeting March 2026 Submission

+354 4206700